🟢 Neurosense Therapeutics Ltd is trading 5.8% up today after Japan grants patent for ALS drug PrimeC

Neurosense Therapeutics Ltd is trading 5.8% up at $0.80 today after the company announced that Japan has granted a patent for its lead ALS drug candidate, PrimeC.

• The stock saw significant momentum in pre-market action, rising as much as 10.4% to $0.83 following the announcement.
• The patent grant serves as the primary catalyst for the move, with the stock outperforming broader positive sentiment in the U.S. markets.
• This milestone strengthens the global intellectual property portfolio for PrimeC as the company continues to develop the candidate for Amyotrophic Lateral Sclerosis (ALS).